267 related articles for article (PubMed ID: 23979758)
21. Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States.
Iqbal N; DeBess EE; Wohrle R; Sun B; Nett RJ; Ahlquist AM; Chiller T; Lockhart SR;
J Clin Microbiol; 2010 Feb; 48(2):539-44. PubMed ID: 20007380
[TBL] [Abstract][Full Text] [Related]
22. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.
Hull CM; Parker JE; Bader O; Weig M; Gross U; Warrilow AG; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4223-32. PubMed ID: 22615281
[TBL] [Abstract][Full Text] [Related]
23. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole.
Espinel-Ingroff A; Aller AI; Canton E; Castañón-Olivares LR; Chowdhary A; Cordoba S; Cuenca-Estrella M; Fothergill A; Fuller J; Govender N; Hagen F; Illnait-Zaragozi MT; Johnson E; Kidd S; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; St-Germain G; Trilles L; Turnidge J
Antimicrob Agents Chemother; 2012 Nov; 56(11):5898-906. PubMed ID: 22948877
[TBL] [Abstract][Full Text] [Related]
24. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
25. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
26. Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.
Nascimento E; Vitali LH; Kress MRVZ; Martinez R
Rev Inst Med Trop Sao Paulo; 2017; 59():e49. PubMed ID: 28793019
[TBL] [Abstract][Full Text] [Related]
27. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
28. Investigation of fluconazole heteroresistance in clinical and environmental isolates of Cryptococcus neoformans complex and Cryptococcus gattii complex in the state of Amazonas, Brazil.
Moreira IMB; Cortez ACA; de Souza ÉS; Pinheiro SB; de Souza Oliveira JG; Sadahiro A; Cruz KS; Matsuura ABJ; Melhem MSC; Frickmann H; de Souza JVB
Med Mycol; 2022 Mar; 60(3):. PubMed ID: 35084497
[TBL] [Abstract][Full Text] [Related]
29. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
30. Antifungal susceptibility of the clinical and environmental strains of Cryptococcus gattii sensu lato in Taiwan.
Lin KH; Lai YC; Lin YP; Ho MW; Chen YC; Chung WH
Mycoses; 2023 Jan; 66(1):13-24. PubMed ID: 35986599
[TBL] [Abstract][Full Text] [Related]
31. A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.
Kim J; Cho YJ; Do E; Choi J; Hu G; Cadieux B; Chun J; Lee Y; Kronstad JW; Jung WH
Fungal Genet Biol; 2012 Nov; 49(11):955-66. PubMed ID: 22975303
[TBL] [Abstract][Full Text] [Related]
32. A CTG Clade Candida Yeast Genetically Engineered for the Genotype-Phenotype Characterization of Azole Antifungal Resistance in Human-Pathogenic Yeasts.
Accoceberry I; Rougeron A; Biteau N; Chevrel P; Fitton-Ouhabi V; Noël T
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038279
[TBL] [Abstract][Full Text] [Related]
33. High Prevalence of HIV-Related Cryptococcosis and Increased Resistance to Fluconazole of the
Yang C; Bian Z; Blechert O; Deng F; Chen H; Li Y; Yang Y; Chen M; Zhan P
Front Cell Infect Microbiol; 2021; 11():723251. PubMed ID: 34790585
[TBL] [Abstract][Full Text] [Related]
34. Correlation of antifungal susceptibility and sequence types within Cryptococcus neoformans VNI from HIV patients, and ERG11 gene polymorphism.
Bive BZ; Sacheli R; Mudogo CN; Zakayi PK; Bontems S; Lelo GM; Hayette MP
J Mycol Med; 2023 Nov; 33(4):101428. PubMed ID: 37651769
[TBL] [Abstract][Full Text] [Related]
35. Calcineurin governs thermotolerance and virulence of Cryptococcus gattii.
Chen YL; Lehman VN; Lewit Y; Averette AF; Heitman J
G3 (Bethesda); 2013 Mar; 3(3):527-39. PubMed ID: 23450261
[TBL] [Abstract][Full Text] [Related]
36. Lipid Flippase Subunit Cdc50 Mediates Drug Resistance and Virulence in Cryptococcus neoformans.
Huang W; Liao G; Baker GM; Wang Y; Lau R; Paderu P; Perlin DS; Xue C
mBio; 2016 May; 7(3):. PubMed ID: 27165800
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo antifungal activities of T-2307, a novel arylamidine, against Cryptococcus gattii: an emerging fungal pathogen.
Nishikawa H; Fukuda Y; Mitsuyama J; Tashiro M; Tanaka A; Takazono T; Saijo T; Yamamoto K; Nakamura S; Imamura Y; Miyazaki T; Kakeya H; Yamamoto Y; Yanagihara K; Mukae H; Kohno S; Izumikawa K
J Antimicrob Chemother; 2017 Jun; 72(6):1709-1713. PubMed ID: 28201509
[TBL] [Abstract][Full Text] [Related]
38. Molecular epidemiology and antifungal susceptibility profiles of clinical
Bandalizadeh Z; Shokohi T; Badali H; Abastabar M; Babamahmoudi F; Davoodi L; Mardani M; Javanian M; Cheraghmakani H; Sepidgar AA; Badiee P; Khodavaisy S; Afshari SAK; Ahmadikia K; Seyedmousavi S
J Med Microbiol; 2020 Jan; 69(1):72-81. PubMed ID: 31750814
[No Abstract] [Full Text] [Related]
39. Astemizole and an analogue promote fungicidal activity of fluconazole against Cryptococcus neoformans var. grubii and Cryptococcus gattii.
Vu K; Gelli A
Med Mycol; 2010 Mar; 48(2):255-62. PubMed ID: 19572230
[TBL] [Abstract][Full Text] [Related]
40. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine.
Espinel-Ingroff A; Chowdhary A; Cuenca-Estrella M; Fothergill A; Fuller J; Hagen F; Govender N; Guarro J; Johnson E; Lass-Flörl C; Lockhart SR; Martins MA; Meis JF; Melhem MS; Ostrosky-Zeichner L; Pelaez T; Pfaller MA; Schell WA; Trilles L; Kidd S; Turnidge J
Antimicrob Agents Chemother; 2012 Jun; 56(6):3107-13. PubMed ID: 22391546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
